2. Disease Areas
  3. Cancer
  4. Breast Cancer
  5. Luminal Breast Cancer

Luminal Breast Cancer

Luminal A breast cancer is a subtype of breast cancer accounting for 40–55% of cases, defined by estrogen receptor (ER) and/or progesterone receptor (PR) positivity, HER2 negativity, and a low Ki-67 proliferation index (<14%), typically presenting as well-differentiated tumors. It is associated with a favorable prognosis and responsiveness to endocrine therapy. Key molecular features include expression of ER/PR, absence of HER2 amplification, and involvement of pathways such as chromatin regulation and acetylation, with HJURP as a related gene. Therapeutic agents like Fulvestrant and Palbociclib are used in treatment. This subtype is linked to tissues including breast and myeloid, and phenotypic traits include increased shRNA abundance and enhanced Salmonella-containing vacuole maturation. Luminal B breast cancer is a hormone receptor-positive (HR+) and HER2-positive breast cancer subtype with a more aggressive phenotype and poorer prognosis compared to luminal A breast cancer. It is characterized by overlapping expression of estrogen and progesterone receptors, increased proliferation, and potential benefit from additional systemic and local therapies. The ERBB2 gene is a key driver, and the condition is linked to pathways such as CREB signaling and ion channel transport. Affected tissues primarily include the breast, and it has associations with familial episodic pain syndrome and mucolipidosis IV.

Luminal Breast Cancer (45):

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-13757
    Tamoxifen Citrate 54965-24-1 99.88%
    Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis. Tamoxifen Citrate can also be used to induce gene knockout in CreER transgenic mice.
    Tamoxifen Citrate
  • HY-13757A
    Tamoxifen 10540-29-1 99.96%
    Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen can also be dissolved in corn oil (HY-Y1888) for use in inducing gene knockout in CreER transgenic mice. Tamoxifen has better solubility in corn oil compared to Tamoxifen Citrate (HY-13757).
    Tamoxifen
  • HY-50767
    Palbociclib 571190-30-2 99.94%
    Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
    Palbociclib
  • HY-P9907
    Trastuzumab 180288-69-1 99.80%
    Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
    Trastuzumab
  • HY-13631E
    Deruxtecan 1599440-13-7 99.94%
    Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813).
    Deruxtecan
  • HY-13636
    Fulvestrant 129453-61-8 99.98%
    Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy.
    Fulvestrant
  • HY-182468
    OP-3136 3056105-63-3
    OP-3136 is a selective KAT6 inhibitor. OP-3136 reduces the proliferative capacity of cancer cells and inhibits cell growth in ER+ breast cancer cell models with overexpressed KAT6. When combined with ER antagonists/degraders or CDK4/6 inhibitors, OP-3136 exhibits synergistic anti-tumor activity in mouse xenograft models. OP-3136 can be used in studies related to HR+/HER2- breast cancer.
    OP-3136
  • HY-181130
    Anticancer agent 299 1414873-26-9
    Anticancer agent 299 (compound P12) is a cell-cycle inhibitor, senescence inducer, apoptosis inducer, and antiproliferative agent. Anticancer agent 299 exhibits selective activity against cancer cells with minimal effects on non-tumoral chondrocyte cells at relevant concentrations. Anticancer agent 299 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.
    Anticancer agent 299
  • HY-N16565
    Piperchabamide B 807618-21-9
    Piperchabamide B is an amide alkaloid. Piperchabamide B can be isolated from the fruits of Piper longum. Piperchabamide B exhibits anticancer activity against acute promyelocytic leukemia, non-small cell lung cancer, and breast cancer.
    Piperchabamide B
  • HY-10218
    Everolimus 159351-69-6 99.85%
    Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities.
    Everolimus
  • HY-15244
    Alpelisib 1217486-61-7 99.95%
    Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.
    Alpelisib
  • HY-16297A
    Abemaciclib 1231929-97-7 99.97%
    Abemaciclib (LY2835219) is a selective and BBB-permeable CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
    Abemaciclib
  • HY-16297
    Abemaciclib methanesulfonate 1231930-82-7 99.95%
    Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective and BBB-permeable CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively.
    Abemaciclib methanesulfonate
  • HY-15777
    Ribociclib 1211441-98-3 99.94%
    RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
    Ribociclib
  • HY-P99843
    Datopotamab 2267989-53-5 99.92%
    Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer.
    Datopotamab
  • HY-P9907A
    Trastuzumab (anti-HER2) 180288-69-1 99.838%
    Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab (anti-HER2)
  • HY-P99380
    Zanidatamab 2169946-15-8 98.56%
    Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity.
    Zanidatamab
  • HY-A0065
    Palbociclib isethionate 827022-33-3 99.98%
    Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
    Palbociclib isethionate
  • HY-P9919
    Durvalumab 1428935-60-7 99.60%
    Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
    Durvalumab
  • HY-13757AR
    Tamoxifen (Standard) 10540-29-1
    Tamoxifen (Standard) is the analytical standard of Tamoxifen (HY-13757A). This product is intended for research and analytical applications. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse.
    Tamoxifen (Standard)